1. Home
  2. Research Topics
  3. Immunology
  4. Human IFN-γ ELISA Kit

Human IFN-γ ELISA Kit

The Human IFNγ ELISA is to be used for the in-vitro quantitative determination of interferon gamma (IFNγ) in human serum, plasma, buffered solutions or cell culture medium.


Species: Human
Catalog No Size
Product Catalog No: 950.000.192 Pack Size: 2 x 96

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Summary

IFNγ, also called Type II interferon, is a homodimeric glycoprotein containing approximately 21 to 24 kD subunits. The human IFNγ gene, situated on chromosome 12, contains three introns; the four exons code for a polypeptide of 166 amino acids, 20 of which constitute the signal peptide.

In contrast to IFNα and IFNβ synthesis, which can occur in any cell, production of IFNγ is a function of T cells and NK cells. All IFNγ inducers activate T cells either in a polyclonal (mitogens or antibodies) or in a clonally restricted, antigen-specific, manner.

Test Principle

A monoclonal antibody specific for IFNγ has been coated onto the wells of the microtiter strips provided.

During the first incubation, IFNγ present in the sample or standard and a monoclonal anti IFNγ antibody conjugated to biotin are simultaneaously incubated.

Following incubation unbound biotinylated anti-IFNγ is removed during a wash step.

Streptavidin-HRP is added and binds to the biotinylated anti IFNγ. After incubation and a wash step a substrate solution reactive with HRP is added to the wells.

A coloured product is formed in proportion to the amount of IFNγ present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm.

References
  1. Botella-Carretero J. I. et al., Eur. J. Endocrinol., 2005; 153(2): 223 – 230
  2. Malmstrom, P.-U. et al., Clin. Cancer Res.,2010; 16(12): 3279-3287
  3. Alonso-Camino, V. et al., Mol Ther Nucleic Acids,2013;2:e93
  4. Altokka-Uzun, G. et al., Cephalalgia, 2015: 333102415570762
  5. Alvarez-Rodriguez, L. et al., Ann Rheum Dis.,2010; 69(01): 263-269.
  6. Bedel, R. et al., Cancer Res.,2011;71(5): 1615-1626
  7. Britschgi, M. et al., J Clin Invest.,2001;107(11): 1433-41
  8. Carcelain G. et al., J. Virol., 2001; 75(1) : 234 – 241
  9. Cerkiene, Z. et al., Am J Reprod Immunol., 2008; 59(2): 118-26.
  10. Chang, Y. et al.,FASEB J.,2010; fj.10-162560
  11. Charbonnier, A. S. et al., J Leukoc Biol.,2003; 73(1): 91-9.
  12. Chenivesse, C. et al., J. Immunol.,2012; 189(1): 128-137
  13. Cohen, N. et al., Blood,2006;107(5): 2037-44.
  14. Corvaisier, M. et al., PLoS Biol.,2012;10(9): e1001395
  15. Cunin, P. et al., J. Immunol.,2011;186(7): 4175-4182.
  16. de Nadai, P. et al., J Immunol.,2006;176(10): 6286-93.
  17. de Pablo, R. et al., J Intensive Care Med.,2011; 26(2): 125-132
  18. Desbois, M. et al., J. Immunol.,2016 ; 197(1): 168-178
  19. Dembinski J. et al., Cytokine, 2003; 21(4): 200 – 206
  20. Diel,F F. et al., Inflammation Research 2003; 52(4): 154-163
  21. Dominguez-Bernal, G. et al.,Parasit Vectors,2015; 8: 629
  22. El Houda Agueznay, N. et al., Clin. & Exp. Immun.,2007 ;150: 114-123
  23. Fahy O. et al., J. immunol., 2002; 168(11): 5912 – 5919
  24. Forsbach, A. et al., J. Immunol.,2008;180(6): 3729-3738.
  25. Gafvelin, G. et al., J Biol Chem., 2007; 282(6): 3778-87.
  26. Giamarellos-Bourboulis, E. J. et al.,PLoS One,2009; 4(12): e8393
  27. Gironella J. et al., Gut, 2005; 54(9): 1244 – 1253
  28. Gopal, A. et al.,Int J Yoga,2011; 4(1): 26-32
  29. Gritzapis, A. D. et al., Br J Cancer,2003; 88(8): 1292-300
  30. Hadley, E. A. et al.,Clin Exp Immunol.,2005; 140(1): 101-8
  31. Hailu A. et al., Am J Trop Med Hyg, 2004; 71(5): 561 – 567
  32. Hammad H. et al., Blood, 2001; 98(4): 1135 – 1141
  33. Hasegawa D. et al., Blood, 1998; 91(8): 2793 – 2799
  34. Hatzfeld-Charbonnier, A. S. et al., J Leukoc Biol.,2007;81: 1179 – 1187
  35. Hohn, H. et al., Clin Exp Immunol.,2003; 131(1): 102-10
  36. Hohn, H. et al., Immunology,2001; 104(3): 278-88
  37. Iwamoto, S. et al., J Leukoc Biol.,2005;78(2): 383-92.
  38. Jain, S. et al., J. Med. Microbiol.,2009; 58(2): 180-184.
  39. Katlama C. et al., AIDS, 2002;16(15): 2027-2034
  40. Keller, M. et al., J Immunol.,2005 ; 175(11): 7678-86.
  41. Kerr J. et al., J. Gen. Virol., 2001; 82(Pt 12): 3011-3019
  42. Laborel-Preneron, E. et al.,PLoS One,2015; 10(10): e0141067
  43. Legrand, F. et al., PLoS One,2009;4(6): e5926
  44. Liao, B. et al., Emerg Microbes Infect.,2015; 4(4): e24
  45. Lindqvist, C. A. et al., Immunology,2010:133(3): 296-306.
  46. Liu, C. P. et al., J Leukoc Biol., 2007; 81: 1276 – 1286
  47. Loo, W. T. et al.,J Transl Med.,2012; 10 Suppl 1: S8
  48. Ludwig, A. T. et al., Cancer Res.,2004;64(10): 3386-90.
  49. Merlo, A. et al., Infect Immun.,2001; 69(10): 6022-9.
  50. Miot, C. et al., Gut,2014: gutjnl-2013-306604
  51. Montcuquet, N. et al., Immunology,2008;125(3): 320-30.
  52. Montero M.T. et al., J. Immunol., 2004; 173(8): 4936 – 4944
  53. Montes, C. L. et al.,Cancer Res.,(2008; 68(3): 870-879.
  54. Nagao, Y. et al., Malar J.,2008; 7: 113.
  55. Naisbitt D.J. et al., J. Pharmacol. Exp. Ther., 2005; 313(3): 1058 – 1065
  56. Naisbitt, D. J. et al., Mol Pharmacol., 2003;63(3): 732-41.
  57. Nilges, K. et al., J Virol.,2003; 77(9): 5464-74.
  58. Pallandre, J. R. et al., Blood, 2008; blood-2007-12-126888.
  59. Perez S A. et al., Blood, 2005; 106(1):158 – 166
  60. Perez, S. A. et al., Blood.,2003;101(9): 3444-50.
  61. Perez, S. A. et al., Int Immunol., 2006;18(1): 49-58.
  62. Piccoli, L., et al.,Clin Dev Immunol., 2012: 483935
  63. Pichavant, M. et al., J Immunol.,2006; 177(9): 5912-9.
  64. Pilch H. et al., Clin. Diagn. Lab. Immunol., 2002; 9(2): 267 – 278
  65. Richardt-Pargmann, D. et al.,Immunobiology,2011; 216(1-2): 12-23.
  66. Rodriguez-Zapata, M. et al., Infect. Immun.,2010; 78:3272-3279
  67. Saroha, M. et al., Hum Vaccin Immunother.,2015; 11(12): 2864-71.
  68. Saverino D. et al., J. immunol., 2002; 168(1): 207 – 215
  69. Schaerli P. et al., J. immunol., 2004; 173(3): 2151 – 2158
  70. Schmitt, C. et al., J Leukoc Biol.,2000; 68(6): 836-44.
  71. Semple, M. G. et al.,PLoS One,2007; 2(10): e1038.
  72. Siren, J. et al., J Gen Virol.,2004; 85(Pt 8): 2357-64.
  73. Spanou, Z. et al., J Am Soc Nephrol.,2006; 17(10): 2919-27.
  74. Stebbing, J. et al., Clin Exp Immunol.,2004; 138(2): 312-6.
  75. Surbatovic, M. et al., Sci Rep.,2015;5: 11355
  76. Sun, Z. et al., J Biomed Res.,2012; 26(6): 456-66
  77. Tang, Y. et al., Am J Trop Med Hyg.,2008; 79(2): 154-158.
  78. Tang, Y. et al.,PLoS One,2010; 5(12): e15631
  79. Tayebi H. et al., J. Immunol. Methods., 1999; 229(1-2): 121 – 130
  80. Tieng, V. et al., Proc Natl Acad Sci.,2002;99(5): 2977-82.
  81. Tluk, S. et al., Int. Immunol.,2009; 21(5): 607-619.
  82. Tully, G. et al., J Immunol.,2005; 174(4): 2174-84.
  83. Trznadel-Grodzka, E. et al., Postepy Hig Med Dosw (Online),2012; 66: 843-7
  84. Trznadel-Grodzka, E. et al., Postepy Hig Med Dosw (Online),2012; 66: 848-54
  85. Vollmer, J. et al., Antimicrob Agents Chemother.,2004; 48(6): 2314-7.
  86. Vollmer, J. et al.,Immunology,2004; 113(2): 212-23.
  87. Wlodarczyk, M. et al., World J Gastroenterol.,2014;20(22):7019-26
  88. Woerly G. et al., J. Exp. Med., 1999; 190(4): 487 -496
  89. Zarkesh-Esfahani S. H. et al., J. Clin. Endocrinol. Metab., 2000;85(9): 3383 – 3390
  90. Zhang, Y. et al., Lupus, 2011; 20: 1172 – 1181
  91. Badal, D. et al.,Indian J Med Res. 2017 Jun;145(6):767-776.
  92. Giris, M. et al.,In Vivo. 2017 Jul-Aug;31(4):657-660.
  93. Molgaard, K. et al.,Gene Ther. 2017 Apr;24(4):208-214.
  94. Owens, G.L. et al.,J Immunother. 2018 Apr;41(3):130-140
Order Enquiry

    Order Enquiry Form

    Documents
    Enquiry